Expert in vitro DDI studies
Evaluating DDIs between co-administered drugs is essential for new drug registration. In vitro DDI studies, particularly those involving cytochrome P450 (CYP) enzymes, are recommended for first-in-human (FiH) trials to help guide participant selection and concomitant medications.
Our assays assess a drug candidate's potential to act as a DDI object or precipitant, complying with international regulatory requirements, including ICH M12 guidelines. Our DDI portfolio includes drug-metabolising enzyme (DME) phenotyping, inhibition, induction and drug transporter phenotyping and inhibition, supporting your drug development process.
Contact Us
Search